Retinal diseases Flashcards
AMD risk factors
age, smoking, +FHx, female, light iris, hyperopia, HTN, hyperchol
what is the difference of soft vs hard drusen?
Hard: nodular thickening of BM of RPE• Soft: focal PED (separation from Bruch’s)
drusen size?
Small 64 mic; med 64-124, large>124
DDX Geographic Atrophy
1) central areolar choroidal dystrophy2) Sorsby macular dystrophy3) NC macular dystrophy
what is Cuticular (Basal Laminar) Drusen?
Type of early hard drusen (age 30-40s)• Many small, uniform, demarcated drusen,better seen on FA with“stars-in-the-sky” appearance• May develop large vitelliform detachment
what is reticular drusen? (PSEUDODRUSEN)
• Interlacing network of 125-250um drusen• First appear in superotemporal macula• Better seen on red-free, NOT on FA /ICG• “Sawtooth” subretinal deposits on OCT
AREDS– Components?
Vitamins C & E, beta carotene, copper, zinc
AREDS study details
25% reduction in progression to advanced AMD– 19% reduction in VA loss over 5 yrs– Criteria?• Bilateral intermediate (many int or 1 large)• Unilateral advanced AMD (wet AMD or GA)– Avoid in smokers?• Beta carotene
AREDS 2 components
Antioxidants w/o beta carotene• Omega-3 fatty acid• Xanthophylls (zeaxanthine, lutein)
Framingham Eye Study:
6% in age >65• 20% in age>75
Choroidal Neovascularization (CNV)• Classificaton?
Type 1– Under RPEType 2– Between RPE + photoreceptorsType 3– Retinal angiomatous proliferations (RAP)
classic CNV - on FA definition
Early hyper + late leakage
occult CNV definition
Stippled/granular early hyper + late stain– 2 types: fibrovascular PED vs. lateleakage of undetermined source
CNV types?
Predominantly Classic (>49% classic)– Minimally Classic (
Retinal Angiomatous Proliferation (RAP) classification
Stage 1– Intraretinal NV / leakageStage 2– Subretinal NV + serous PEDStage 3– Choroidal NV + fibrovascular PED– FA: retinochoroidal anastamoses
what is Pegaptanib (Macugen)
pegylated anti-VEGF RNA aptamer• binds VEGF 165• 0.3mg
what is Ranibizumab (Lucentis)
its:48kD Fab of Mab (
Bevacizumab (Avastin)
full-length Mab + Fc• targets VEGF-A• 1.25mg, 2.5mg
Aflibercept (Eylea)
ligand-binding domain of VEGFR ½ + IgG Fc• binds VEGF-A & placental-like GF• 2mg, 4mg
PDT- Regular vs. Reduced fluence?
Regular: 600mW/cm2- Reduced: 300mW/cm2
Vision Study
Macugen q6wks x 48wks > sham– improved VA in all CNV
MARINA
Lucentis q4wks x 2yrs > sham– Minimally-classic or occult w/o classic CNV
ANCHOR
Lucentis q4wks x 2yrs > PDT q3mo PRN– Predominantly-classic CNV
PIER
Lucentis q4wks x 3 then q12wks– Steady decline after 3mo c/w q4wks
PrONTO
Lucentis q4wks x 3 then PRN (VA loss + fluid, CRTinc, mac hem, new cl CNV, persistent fluid s/p inj)– Comparable to q4wks; 5.6inj/yr, but q4wk visits
SUSTAIN
Lucentis q4wks x 3 then PRN (VA loss, CRT inc)– Comparable to q4wks; 5.3inj/yr, but q4wk visits
HORIZON
MARINA/ANCHOR/FOCUS pts tx w/ PRN Lucentisq4wks s/p 2yrs– Continued less frequent dosing -> VA loss
CATT
Lucentis = Avastin q4wks or PRN in VA ( Avastin q4wks or PRN in OCT fluid (~10%)– Avastin > Lucentis in adverse events (24 vs 19%)
FOCUS
Lucentis + PDT > PDT alone– Predominantly-classic CNV
SUMMIT (MONT BLANC, DENALI, EVEREST)
Lucentis + PDT = Lucentis alone– Except IPCV (Lucentis + PDT > Lucentis)
CABERNET
Lucentis + epimacular brachy vs Lucentis
RADICAL
– Lucentis + PDT + Dexamethasone vs Lucentis
VIEW1 & 2
Eylea q1mo x 3 -> q2mo = Lucentis q1mo
HARBOR
Lucentis 0.5mg q4wks vs PRN vs 2mg q4wks vsPRN
AMD clinical trials
Marina - lucentisAnchor - lucentisCATT - avastinVIEW- Eylea
DME clinical trials
RISE & RIDE - lucentisDRCR.net - avastinVIVID/VISTA-DaVINCI- EyleaDRCR.net - triamcinoloneRetisert - ElliotFAME- Illuvien
RVO clinical trials
BRAVO/CRUISE - lucentisCRAVE - AvastinCOpernicus/Galileo/Vibrant - EyleaSCORE - triamcinoloneJaffe/Jain - Retisert
Causes of CNV?
1) AMD2) Myopic degeneration3) POHS4) Angioid streaks5) IPCV
what is Idiopathic Polypoidal ChoroidalVasculopathy (IPCV or PCV)
Multifocal, recurrent serous PEDs– Saccular choroidal outpouchings– More common in?• African-Caribbeans & Asians(accounts for >30% of exudativemaculopathy in Asian populations)
FA in Idiopathic Polypoidal ChoroidalVasculopathy (IPCV or PCV)
Early hyperfluorescent polyps andhypofluorescent halos• Polyps better seen on ICG
PCV treatment
Anti-VEGF, PDT, or combined• Only disease in SUMMIT trial tohave improved response tocombined anti-VEGF + PDT
what is Sorsby macular dystrophy
looks like GA- autosomal dominant- inherited dystrophy- by TIMP3 gene- normal vision until age of 40’s- then develop BILATERAL multiple CNVs- later looks like GA with lots of pigment clumps, this is perhaps the differentiation- early they have mid-peripheral drusen, night vision problems
Malattia levintinese
-drusen distributed radially on the macula.- very similar to AMD-EFEMP1 gene, malattia levintinese is now thought to be a variant of Doyne’s disease.
Doyne’s honeycomb retinal dystrophy
-similar to those of AMD:-Symptoms typically arise during the fourth or fifth decade of life.- autosomal dominant pattern of inheritance.gene EGF-containing fibrillin-like extracellular matrix protein, abbreviated as EFEMP1. The protein, whose function is
CACD Central areolar macular dystrophy
-hereditaryatrophy of RPE and choriocapillaris-AD-gene: PRPH2 (previously known as RDS/peripherin
NC macular dystrophy
The disorder was initially described in a family of Irish descent in North Carolina, and affected individuals have been identified in European, Asian and South American families as well.
RAP lesions
its an occult CNV with proliferation of intraretinal capillaries in the paramacular area with contiguous telangiectasic response.Stage 1: intraretinial capillaries proliferationstage 2 subretinalstage 3 PEDstage 4 cnv- clinically similar to patients with AMD. -, these patients tend to be slightly older (80) than the patients with both classic and occult CNV. -bilateral, -lesions presenting juxtafoveally.-clinical features of RAP include retinal and preretinal hemorrhages as well as pigment epithelial detachments.